Allergan PLC. Company Profile (NYSE:AGN)

About Allergan PLC. (NYSE:AGN)

Allergan PLC. logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:AGN
  • CUSIP: 01849010
  • Web:
  • Market Cap: $62.94 billion
  • Outstanding Shares: 334,306,000
Average Prices:
  • 50 Day Moving Avg: $212.48
  • 200 Day Moving Avg: $230.71
  • 52 Week Range: $182.80 - $256.80
  • Trailing P/E Ratio: 5.74
  • Foreward P/E Ratio: 10.95
  • P/E Growth: 1.03
Sales & Book Value:
  • Annual Revenue: $15.07 billion
  • Price / Sales: 4.18
  • Book Value: $210.39 per share
  • Price / Book: 0.89
  • Annual Dividend: $2.80
  • Dividend Yield: 1.4%
  • EBITDA: $6.15 billion
  • Net Margins: 79.17%
  • Return on Equity: 7.37%
  • Return on Assets: 4.17%
  • Debt-to-Equity Ratio: 0.38%
  • Current Ratio: 1.21%
  • Quick Ratio: 1.10%
  • Average Volume: 2.77 million shs.
  • Beta: 1.15
  • Short Ratio: 3.43

Frequently Asked Questions for Allergan PLC. (NYSE:AGN)

What is Allergan PLC.'s stock symbol?

Allergan PLC. trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan PLC. pay dividends? What is the dividend yield for Allergan PLC.?

Allergan PLC. announced a quarterly dividend on Wednesday, August 2nd. Stockholders of record on Friday, August 18th will be given a dividend of $0.70 per share on Friday, September 15th. This represents a $2.80 annualized dividend and a dividend yield of 1.49%. The ex-dividend date is Wednesday, August 16th. View Allergan PLC.'s Dividend History.

How will Allergan PLC.'s stock buyback program work?

Allergan PLC. announced that its board has approved a share buyback program on Tuesday, September 26th 2017, which permits the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's board believes its stock is undervalued.

How were Allergan PLC.'s earnings last quarter?

Allergan PLC. (NYSE:AGN) posted its quarterly earnings data on Thursday, August, 3rd. The company reported $4.02 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $3.95 by $0.07. The business earned $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business's revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company earned $3.35 EPS. View Allergan PLC.'s Earnings History.

When will Allergan PLC. make its next earnings announcement?

Allergan PLC. is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Allergan PLC..

What guidance has Allergan PLC. issued on next quarter's earnings?

Allergan PLC. issued an update on its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of $16.05-16.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.08. The company issued revenue guidance of $15.85-16.05 billion, compared to the consensus revenue estimate of $15.81 billion.

Where is Allergan PLC.'s stock going? Where will Allergan PLC.'s stock price be in 2017?

19 analysts have issued 12 month price targets for Allergan PLC.'s stock. Their forecasts range from $193.00 to $280.00. On average, they expect Allergan PLC.'s share price to reach $251.76 in the next year. View Analyst Ratings for Allergan PLC..

What are analysts saying about Allergan PLC. stock?

Here are some recent quotes from research analysts about Allergan PLC. stock:

  • 1. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi and Vraylar, are supporting sales growth. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, Allergan is facing generic competition for legacy brands like Namenda and Asacol HD as well as patent challenges for some of the other products in its branded portfolio, which concerns us. In October, a Texas federal district court invalidated four of the six patents covering Restasis, Allergan’s second best-selling drug, potentially opening doors for early generic competition. Also, competition for key growth drivers, Restasis and Linzess, is an investor concern. Allergan’s shares have underperformed the broader industry in the past one month.  Estimates have also declined slightly ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/17/2017)
  • 2. Cantor Fitzgerald analysts commented, "Allergan announced mixed top-line results from its Phase 2b study of CVC for NASH. The Street was waiting for this, and the delay relative to Street expectations had been one reason the stock has been weak." (9/22/2017)
  • 3. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)

Who are some of Allergan PLC.'s key competitors?

Who owns Allergan PLC. stock?

Allergan PLC.'s stock is owned by a number of of retail and institutional investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.10%), Cacti Asset Management LLC (0.07%), Sit Investment Associates Inc. (0.03%), Verde Servicos Internacionais S.A. (0.03%), PGGM Investments (0.02%) and Park National Corp OH (0.01%). Company insiders that own Allergan PLC. stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan PLC..

Who sold Allergan PLC. stock? Who is selling Allergan PLC. stock?

Allergan PLC.'s stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Bridges Investment Counsel Inc., Sit Investment Associates Inc., Verde Servicos Internacionais S.A., Howe & Rusling Inc., Windward Capital Management Co. CA and Bristlecone Advisors LLC. Company insiders that have sold Allergan PLC. stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..

Who bought Allergan PLC. stock? Who is buying Allergan PLC. stock?

Allergan PLC.'s stock was bought by a variety of institutional investors in the last quarter, including Cacti Asset Management LLC, Robeco Institutional Asset Management B.V., Assenagon Asset Management S.A., Sumitomo Life Insurance Co., Park National Corp OH, Wealth Enhancement Advisory Services LLC, Fisher Asset Management LLC and Meeder Asset Management Inc.. Company insiders that have bought Allergan PLC. stock in the last two years include Brent L Saunders and Maria Teresa Hilado. View Insider Buying and Selling for Allergan PLC..

How do I buy Allergan PLC. stock?

Shares of Allergan PLC. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan PLC.'s stock price today?

One share of Allergan PLC. stock can currently be purchased for approximately $188.28.

MarketBeat Community Rating for Allergan PLC. (NYSE AGN)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  891 (Vote Outperform)
Underperform Votes:  394 (Vote Underperform)
Total Votes:  1,285
MarketBeat's community ratings are surveys of what our community members think about Allergan PLC. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Allergan PLC. (NYSE:AGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 8 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $251.76 (33.72% upside)
Consensus Price Target History for Allergan PLC. (NYSE:AGN)
Price Target History for Allergan PLC. (NYSE:AGN)
Analysts' Ratings History for Allergan PLC. (NYSE:AGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/20/2017Cowen and CompanySet Price TargetBuy$400.00 -> $280.00N/AView Rating Details
10/19/2017Royal Bank Of CanadaReiterated RatingOutperform -> Outperform$277.00 -> $250.00N/AView Rating Details
10/19/2017Citigroup Inc.Lower Price TargetBuy$280.00 -> $240.00N/AView Rating Details
10/19/2017MizuhoDowngradeBuy -> Neutral$193.00 -> $193.00N/AView Rating Details
10/18/2017Edward JonesReiterated RatingBuy -> HoldN/AView Rating Details
10/18/2017Sanford C. BernsteinSet Price TargetBuy$296.00 -> $252.00N/AView Rating Details
10/18/2017Wells Fargo & CoReiterated RatingOutperform$258.00N/AView Rating Details
10/17/2017Deutsche Bank AGSet Price TargetBuy$251.00N/AView Rating Details
10/17/2017Credit Suisse GroupSet Price TargetOutperform$266.00 -> $243.00N/AView Rating Details
10/16/2017J P Morgan Chase & CoReiterated RatingBuy$275.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesSet Price TargetHold$227.00N/AView Rating Details
10/12/2017Cantor FitzgeraldSet Price TargetHold$231.00N/AView Rating Details
10/2/2017Barclays PLCReiterated RatingEqual WeightLowView Rating Details
9/20/2017Morgan StanleyDowngradeOverweight -> Equal Weight$284.00 -> $228.00MediumView Rating Details
8/14/2017ArgusReiterated RatingBuy$280.00LowView Rating Details
5/10/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$262.00HighView Rating Details
2/9/2017Leerink SwannBoost Price TargetBuy$280.00N/AView Rating Details
12/23/2016Bank of America CorporationReiterated RatingBuy$280.00N/AView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James Financial, Inc.Lower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Allergan PLC. (NYSE:AGN)
Earnings by Quarter for Allergan PLC. (NYSE:AGN)
Earnings History by Quarter for Allergan PLC. (NYSE AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017$4.19N/AView Earnings Details
8/3/2017Q2 2017$3.95$4.02$3.95 billion$4.01 billionViewListenView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.53 billion$3.57 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan PLC. (NYSE:AGN)
2017 EPS Consensus Estimate: $16.31
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$3.33$3.55$3.44
Q2 20172$4.00$4.07$4.04
Q3 20173$4.03$4.16$4.09
Q4 20173$4.67$4.84$4.74
(Data provided by Zacks Investment Research)


Current Dividend Information for Allergan PLC. (NYSE:AGN)
Most Recent Dividend:9/15/2017
Annual Dividend:$2.80
Dividend Yield:1.49%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:9.95% (Trailing 12 Months of Earnings)
17.27% (Based on This Year's Estimates)
16.28% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Allergan PLC. (NYSE:AGN)

Dividend History by Quarter for Allergan PLC. (NYSE AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Allergan PLC. (NYSE:AGN)
Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 81.94%
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.08View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Allergan PLC. (NYSE:AGN)
Latest Headlines for Allergan PLC. (NYSE:AGN)
DateHeadline logoAllergan PLC. (AGN) Given Outperform Rating at Cowen and Company - October 20 at 9:10 AM logoFY2019 EPS Estimates for Allergan PLC. (AGN) Lowered by Analyst - October 19 at 4:14 PM logoImprimis Launches 99-Cent Generic Drug To Compete With Allergan's Restasis - October 19 at 4:10 PM logoConatus Entrusts Keith W. Marshall With Key Management Roles - October 19 at 4:10 PM logoCompany News For Oct 19, 2017 - October 19 at 4:10 PM logoAllergan: All In or Fall Out? - October 19 at 4:10 PM logoAllergan's Hard Fall Is Not Enough of a Reason to Buy - October 19 at 4:10 PM logoRoyal Bank Of Canada Reaffirms "Outperform" Rating for Allergan PLC. (AGN) - October 19 at 8:18 AM logoIs a Breakup Allergan's Best Bet? - October 18 at 4:42 PM logoMohawk tribe sues Microsoft, Amazon for patent infringement - October 18 at 4:42 PM logoAllergan Shares Are Ready for a 30% Bounce Within Days - October 18 at 4:42 PM logoEquities Analysts Offer Predictions for Allergan PLC.'s FY2020 Earnings (AGN) - October 18 at 3:02 PM logoShire feels Allergan's Restasis patent pain, shares down 3% - October 18 at 12:20 PM logoAllergan PLC. (AGN) Stock Rating Reaffirmed by Sanford C. Bernstein - October 18 at 10:59 AM logoEdward Jones Reaffirms Hold Rating for Allergan PLC. (AGN) - October 18 at 10:59 AM logoAllergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall - October 17 at 9:34 PM logoAllergan: How Bad Is It? - October 17 at 4:31 PM logoToday's Research Reports on Stocks to Watch: Allergan and Gilead Sciences - October 17 at 4:31 PM logoHow Allergan's 'Public Relations Backlash' Deepened This Week - October 17 at 4:31 PM logoHere's How Drug Companies Game the Patent System - October 17 at 4:31 PM logoAnd For Allergen's Next Trick..Filling a $1.5 Billion Hole? - October 17 at 4:31 PM logoZacks: Brokerages Expect Allergan PLC. (AGN) Will Post Quarterly Sales of $4.03 Billion - October 17 at 9:52 AM logoCredit Suisse Group Reaffirms Outperform Rating for Allergan PLC. (AGN) - October 17 at 9:22 AM logoAllergan (AGN) Says It's Disappointed by Adverse Trial Decision Concerning RESTASIS 0.05% Patents - October 17 at 2:33 AM logoAllergan patent suit loss sends stock down 5% - October 16 at 4:30 PM logoAllergan to Present New Data at the World Congress of Gastroenterology at ACG 2017 - October 16 at 4:30 PM logoAllergan's Restasis patents invalidated by federal judge - October 16 at 4:29 PM logoAllergan stock drops 5% after judge decides against company on key dry eye product - October 16 at 4:29 PM logoU.S. District Court for the Eastern District of Texas Issues Adverse Trial Decision Concerning RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patents - October 16 at 4:29 PM logoU.S. judge in Texas invalidates Allergan patents on Restasis - October 16 at 4:29 PM logoAllergan Tanks After Judge Invalidates Restasis Patents - October 16 at 4:29 PM logoAllergan Loses a Patent Battle…Has It Lost the War? - October 16 at 4:29 PM logoAllergan will repeal Restasis patent decision - October 16 at 4:29 PM logo[$$] Allergan Loses Patent Fight in Federal Court - October 16 at 4:29 PM logoAllergan patent suit loss sends stock down 4% - October 16 at 4:29 PM logoJudge invalidates Allergan patents on dry-eye medicine Restasis - October 16 at 3:37 PM logoJ P Morgan Chase & Co Reiterates Buy Rating for Allergan PLC. (AGN) - October 16 at 3:32 PM logoPiper Jaffray Companies Analysts Give Allergan PLC. (AGN) a $227.00 Price Target - October 14 at 12:12 PM logoAllergan Q3 2017: Earnings Preview - Seeking Alpha - October 14 at 1:40 AM logoWells Fargo & Company Analysts Give Allergan PLC. (AGN) a $276.00 Price Target - October 13 at 9:36 AM logoAllergan settles with one of four companies contesting Restasis patent - October 12 at 9:22 PM logoAllergan PLC. (AGN) PT Set at $231.00 by Cantor Fitzgerald - October 12 at 6:26 PM logoDecember 1st Options Now Available For Allergan (AGN) - October 12 at 4:19 PM logoArdelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up - October 12 at 4:19 PM logoAllergan Announces Settlement on RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05% Patent Litigation with InnoPharma, Inc. - October 12 at 4:19 PM logoAllergan PLC. (AGN) Given Buy Rating at Cowen and Company - October 12 at 9:46 AM logoAllergan (AGN) Says FDA Accepted NDA for Ulipristal Acetate for Uterine Fibroids - October 11 at 4:57 PM logoNotable Wednesday Option Activity: ABBV, AGN, REGN - October 11 at 4:57 PM logoAllergan's Uterine Fibroids Candidate's NDA Accepted by FDA - October 11 at 4:57 PM logoFavorite stock picks from one of Wall Street's top biotech analysts - October 11 at 4:57 PM



Allergan PLC. (AGN) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.